Global Recombinant Human Granulocyte Colony-Stimulating Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Recombinant Human Granulocyte Colony-Stimulating Market Research Report 2024
Granulocyte-colony stimulating factor (G-CSF or GCSF), also known as colony-stimulating factor 3 (CSF 3), is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream.
Functionally, it is a cytokine and hormone, a type of colony-stimulating factor, and is produced by a number of different tissues. The pharmaceutical analogs of naturally occurring G-CSF are called filgrastim and lenograstim.
G-CSF also stimulates the survival, proliferation, differentiation, and function of neutrophil precursors and mature neutrophils.
According to Mr Accuracy reports’s new survey, global Recombinant Human Granulocyte Colony-Stimulating market is projected to reach US$ million in 2034, increasing from US$ million in 2024, with the CAGR of % during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Recombinant Human Granulocyte Colony-Stimulating market research.
Key manufacturers engaged in the Recombinant Human Granulocyte Colony-Stimulating industry include Amgen, Qilu Pharmaceutical, Shijiazhuang Pharmaceutical, Kyowa Hakko Kirin, Gensci, Amoytop Biotech, Hangzhou Jiuyuan, Huaxin and Triprime, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2024.
When refers to consumption region, % volume of Recombinant Human Granulocyte Colony-Stimulating were sold to North America, Europe and Asia Pacific in 2024. Moreover, China, plays a key role in the whole Recombinant Human Granulocyte Colony-Stimulating market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Recombinant Human Granulocyte Colony-Stimulating market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Amgen
Qilu Pharmaceutical
Shijiazhuang Pharmaceutical
Kyowa Hakko Kirin
Gensci
Amoytop Biotech
Hangzhou Jiuyuan
Huaxin
Triprime
Sinovac
Zhaoke
Kawin
Segment by Type
Lenograstim (Granocyte)
Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim)
Others
Chemotherapy Induced Neutropenia
Before Blood Donation
Stem Cell Transplants
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Recombinant Human Granulocyte Colony-Stimulating report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Functionally, it is a cytokine and hormone, a type of colony-stimulating factor, and is produced by a number of different tissues. The pharmaceutical analogs of naturally occurring G-CSF are called filgrastim and lenograstim.
G-CSF also stimulates the survival, proliferation, differentiation, and function of neutrophil precursors and mature neutrophils.
According to Mr Accuracy reports’s new survey, global Recombinant Human Granulocyte Colony-Stimulating market is projected to reach US$ million in 2034, increasing from US$ million in 2024, with the CAGR of % during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Recombinant Human Granulocyte Colony-Stimulating market research.
Key manufacturers engaged in the Recombinant Human Granulocyte Colony-Stimulating industry include Amgen, Qilu Pharmaceutical, Shijiazhuang Pharmaceutical, Kyowa Hakko Kirin, Gensci, Amoytop Biotech, Hangzhou Jiuyuan, Huaxin and Triprime, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2024.
When refers to consumption region, % volume of Recombinant Human Granulocyte Colony-Stimulating were sold to North America, Europe and Asia Pacific in 2024. Moreover, China, plays a key role in the whole Recombinant Human Granulocyte Colony-Stimulating market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Recombinant Human Granulocyte Colony-Stimulating market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Amgen
Qilu Pharmaceutical
Shijiazhuang Pharmaceutical
Kyowa Hakko Kirin
Gensci
Amoytop Biotech
Hangzhou Jiuyuan
Huaxin
Triprime
Sinovac
Zhaoke
Kawin
Segment by Type
Lenograstim (Granocyte)
Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim)
Others
Segment by Application
Chemotherapy Induced Neutropenia
Before Blood Donation
Stem Cell Transplants
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Recombinant Human Granulocyte Colony-Stimulating report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices